TAMIFLU

Compare TAMIFLU  to:
Compare
Compare
TAMIFLU (Oseltamivir) 30mg, 45mg, 75mg capsules by Roche Laboratories

Generic Name for TAMIFLU

Oseltamivir (as phosphate) 30mg, 45mg, 75mg; caps.

Legal Classification:

Rx

Pharmacological Class for TAMIFLU

Neuraminidase inhibitor.

Manufacturer of TAMIFLU

Roche Laboratories

Indications for TAMIFLU

Treatment of uncomplicated acute illness due to influenza infection in patients ≥1year of age who have been symptomatic for ≤2days. Prophylaxis of influenza in patients ≥1year of age.

Adult dose for TAMIFLU

Start within 2 days of symptom onset or exposure. ≥13yrs: Treatment: 75mg twice daily for 5 days; CrCl 10–30mL/min: 75mg once daily for 5 days. Prophylaxis: after close contact with infected individual: 75mg once daily for at least 10 days; during community outbreak: 75mg once daily for up to 6 weeks; CrCl 10–30mL/min: 75mg every other day or 30mg once daily.

Children's dosing for TAMIFLU

<1yr: not recommended. 1–12yrs: Start within 2 days of symptom onset. Treatment: Treat for 5 days. ≤15kg: 30mg twice daily; 16–23kg: 45mg twice daily; 24–40kg: 60mg twice daily; >40kg: 75mg twice daily. Prophylaxis: Treat for 10 days. ≤15kg: 30mg once daily; 16–23kg: 45mg once daily; 24–40kg: 60mg once daily; >40kg: 75mg once daily.

Also:

Precautions for TAMIFLU

Not a substitute for influenza vaccination. Hepatic impairment. Chronic cardiac or respiratory disease. Immunocompromised. Monitor for signs of abnormal behavior (esp. in children). Pregnancy (Cat.C). Nursing mothers.

Interactions for TAMIFLU

Do not administer live attenuated influenza vaccine within 2 weeks prior or 48 hrs after treatment.

Adverse Reactions for TAMIFLU

GI upset, bronchitis, headache, insomnia, vertigo, fatigue; possible neuropsychiatric events (eg, hallucinations, delirium, abnormal behavior).

How is TAMIFLU supplied?

Caps—10
Susp—25mL (w. oral dispenser)

Related Disease:

Influenza~antivirals

Related Resources

FDA reviews cardiac risk of Invirase in combination with Norvir

February 23, 2010

The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).

Heat-stable Norvir tablets approved

February 16, 2010

The FDA has approved a heat-stable formulation of Norvir tablets (ritonavir, from Abbott) that can be stored at room temperature.

Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension

January 29, 2010

The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.

Prezista labeling updated to include 96-week data

January 28, 2010

Tibotec Therapeutics announced that the FDA has approved an updated label for Prezista (darunavir tablets) which includes 96-week data from the ARTEMIS and TITAN studies.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).